Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142770 | 1.00 | HPGD (0.33) | HPGDCES2CES1NPC1RAB9A | |
| SCHEMBL8718920 | 1.00 | HPGD (0.33) | HPGDCES2CES1NPC1RAB9A | |
| SCHEMBL1799677 | 0.90 | HPGD (0.33) | HPGDCES2CES1NPC1RAB9A | |
| SCHEMBL2476284 | 0.90 | GSK3B (0.32) | CES2CES1LMNAALDH1A1GAA | |
| SCHEMBL2476289 | 0.90 | GSK3B (0.32) | CES2CES1LMNAALDH1A1GAA | |
| SCHEMBL8112010 | 0.79 | KMT2A (0.33) | HPGDCES2CES1L3MBTL1LMNA | |
| SCHEMBL8112015 | 0.79 | KMT2A (0.33) | HPGDCES2CES1L3MBTL1LMNA | |
| SCHEMBL9614440 | 0.78 | HPGD (0.33) | HPGDCES2CES1CHRM2ADRA2B | |
| SCHEMBL11104413 | 0.78 | HPGD (0.33) | HPGDCES2CES1CHRM2ADRA2B | |
| SCHEMBL16446965 | 0.78 | HPGD (0.33) | HPGDCES2CES1CHRM2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266863-B2 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2016-02-23 | — | — | US | claimed |
| EP-2371825-B1 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2014-01-08 | — | — | EP | claimed |
| US-20110245485-A1 | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE | CHEMI SPA (IT) | 2011-10-06 | — | — | US | claimed |
| EP-2371825-A1 | Process for the synthesis of azacitidine and decitabine | Chemi SPA (IT) | 2011-10-05 | — | — | EP | claimed |
| US-9266863-B2 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2016-02-23 | — | — | US | disclosed |
| EP-2371825-B1 | Process for the synthesis of azacitidine and decitabine | CHEMI SPA (IT) | 2014-01-08 | — | — | EP | disclosed |
| US-20110245485-A1 | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE | CHEMI SPA (IT) | 2011-10-06 | — | — | US | disclosed |
| EP-2371825-A1 | Process for the synthesis of azacitidine and decitabine | Chemi SPA (IT) | 2011-10-05 | — | — | EP | disclosed |
| EP-0548798-A1 | Antiviral agent | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
| US-4663446-A | BACTERICIDES, POLYMERASE INHIBITORS | TRUSTEES OF THE UNIV. OF MASSACHUSETTS (US) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245485-A1 | PROCESS FOR THE SYNTHESIS OF AZACITIDINE AND DECITABINE | DNMT1, TET1, TET2 | HPGD 2808/4885CES2 982/4885CES1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.